CD8A and neoplasm: The therapeutic efficacy largely stems from the anti-tumor activity of CD8+ T-cells, which target malignant cells by recognizing tumor-associated neoantigens and tumor-specific antigens on their surface (As shown in Fig 1a) [15–17].